Currently, there are 17.61M common shares owned by the public and among those 17.27M shares have been available to trade.
The company’s stock has a 5-day price change of -10.89% and 2.43% over the past three months. RIGL shares are trading 13.38% year to date (YTD), with the 12-month market performance up to 17.43% higher. It has a 12-month low price of $7.48 and touched a high of $29.82 over the same period. RIGL has an average intraday trading volume of 231.71K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -24.93%, -18.08%, and 19.26% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Rigel Pharmaceuticals (NASDAQ: RIGL) shares accounts for 67.84% of the company’s 17.61M shares outstanding.
It has a market capitalization of $289.59M and a beta (3y monthly) value of 1.28. The stock’s trailing 12-month PE ratio is 75.90, while the earnings-per-share (ttm) stands at $0.22. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.79% over the week and 7.72% over the month.
Analysts forecast that Rigel Pharmaceuticals (RIGL) will achieve an EPS of 0.33 for the current quarter, 0.18 for the next quarter and 1.04 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.13 while analysts give the company a high EPS estimate of 0.13. Comparatively, EPS for the current quarter was 0.0 a year ago. Earnings per share for the fiscal year are expected to increase by 120.53%, and 240.01% over the next financial year.
Looking at the support for the RIGL, a number of firms have released research notes about the stock. Piper Sandler stated their Neutral rating for the stock in a research note on April 03, 2023, with the firm’s price target at $2. Piper Sandler was of a view on June 08, 2022 that the stock is Neutral, while Cantor Fitzgerald gave the stock Neutral rating on June 08, 2022, issuing a price target of $6- $1. B. Riley Securities on their part issued Neutral rating on March 23, 2022.
